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Abstract
Background: Public and patient involvement in the design of people-centred care and research is vital for
communities whose needs are underserved, as are people with rare diseases. Innovations devised collectively by
patients, caregivers, professionals and other members of the public can foster transformative change toward more
responsive services and research. However, attempts to involve lay and professional stakeholders in devising
community-framed strategies to address the unmet needs of rare diseases are lacking. In this study, we engaged
with the community of Congenital Disorders of Glycosylation (CDG) to assess its needs and elicit social innovations
to promote people-centred care and research.
Methods: Drawing on a qualitative study, we conducted three think tanks in France with a total of 48 participants,
including patients/family members (n = 18), health care professionals (n = 7), researchers (n = 7) and people
combining several of these roles (n = 16). Participants came from 20 countries across five continents. They were
selected from the registry of the Second World Conference on CDG through heterogeneity and simple random
sampling. Inductive and deductive approaches were employed to conduct interpretational analysis using open, axial
and selective coding, and the constant-comparison method to facilitate the emergence of categories and core themes.
Results: The CDG community has unmet needs for information, quality health care, psychosocial support and
representation in decision-making concerned with care and research. According to participants, these needs can be
addressed through a range of social innovations, including peer-support communities, web-based information
resources and a CDG expertise platform.
Conclusion: This is one of the few studies to engage lay and professional experts in needs assessment and innovation
for CDG at a global level. Implementing the innovations proposed by the CDG community is likely to have ethical,
legal and social implications associated with the potential donation of patients’ clinical and biological material that
need to be assessed and regulated with involvement from all stakeholders. To promote people-centred care for the
CDG community, and increase its participation in the governance of care and research, it is necessary to create
participatory spaces in which the views of people affected by CDG can be fully expressed.
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Background
Public and patient involvement is a fundamental element
in implementing patient-oriented research and improving
the design and provision of people-centred care [1–3]. By
enabling lay and expert knowledge to come to the fore,
public and patient involvement can help promote needs-
driven research, as well as care practices centred on peo-
ple’s needs, values and preferences [4, 5]. This is particu-
larly relevant for people with rare diseases whose needs
are often underserved [6–9]. Yet, only a few studies have
focused on identifying patient-framed solutions for the
unmet needs of rare diseases [6, 10], and attempts to in-
volve both lay and professional experts in dialogue about
innovations to address them appear to be lacking. Disre-
garding public and patient perspectives risks undermining
the societal relevance and acceptability of research [11], as
well as health care systems’ responsiveness to people’s
right to quality care [12]. In this study, we engaged with
the community of Congenital Disorders of Glycosylation
(CDG) to assess its needs and elicit its views on how to
achieve people-centred care and research.
CDG are a group of rare inherited metabolic diseases
caused by defects in glycosylation [13]. Glycosylation is
present in all tissues and organs. Consequently, errors in
glycosylation can have a large spectrum of consequences
(e.g. affecting the muscular, cardiovascular, immune and
central nervous systems) [14] and clinical manifestations
(e.g. cardiac disease, severe developmental delay) [15–17].
Signs and symptoms typically present from infancy and
vary across CDG types [18]. The most common type of
CDG – PMM2-CDG – has an estimated incidence of
1:20,000 live births, affecting males and females in a simi-
lar way [19]. Mortality in the early years is approximately
20% [18]. Affected patients can survive into adulthood,
but dependence on care services and caregivers is high
throughout the lifespan [18]. Although CDG is one of the
fastest growing groups of monogenetic diseases [20], little
investment has been made in treatment development and
most CDG types lack an effective therapy [21]. To reduce
the burden of CDG, it is necessary to involve patients,
caregivers, professionals and other members of the public
in setting priorities for research and developing care
centred on patients’ needs.
Eliciting community-framed solutions is expected to
advance tailor-made innovations and effect transforma-
tive change [22]. When these innovations are geared to-
wards solving complex social problems such as
overcoming services’ limited responsiveness they can be
termed social innovations [23]. Social innovations have
the potential to harness latent or unrealised value [24]
by fostering collaboration between previously discon-
nected groups and uncovering new understandings that
challenge preconceived ideas [25]. In other words, they
can join stakeholders from various backgrounds, and
promote public and patient involvement in health
decision-making.
Drawing on a qualitative study that deployed think
tanks with lay and professional stakeholders, this paper
delves on the experiences of the CDG community to
identify its unmet needs and explore innovations that
may help address them. In doing so, it aims to facilitate
the emergence of alternative forms of knowledge, ex-
pand the evidence base for the needs of people affected
by rare diseases, and elicit tailor-made innovations to
foster change toward quality care and research.
Methods
A qualitative study was undertaken deploying three
think tanks – a form of group interviews particularly
suitable to inquire and elicit debate on previously de-
fined topics among large and heterogeneous stakeholder
groups [26, 27]. A semi-structured interview guide was
used in all think tanks. It addressed two topic questions:
1) what are the challenges experienced by people living
with or caring for patients with CDG? And, 2) what
strategies can be used to overcome those challenges? Re-
search ethics approval was obtained following project
approval by the Foundation for Science and Technology
(Portuguese Ministry of Science, Technology and Higher
Education). The study followed the Code of Ethics of the
International Sociological Association. All participants
provided prior written informed consent to participate
in the study and to audio record the think tanks. Think
tanks were held in August 2015, in Lyon, France, during
the Second World Conference on CDG in a venue spe-
cifically assigned for that purpose.
Data collection
Participants’ selection involved the sequential employment
of probability and non-probability sampling techniques [28]
using parameters collected from the registry of the Second
World Conference on CDG. Heterogeneity sampling was
used to ensure maximum variation regarding participants’
experiences and perspectives based on two criteria: type of
connection to CDG (i.e. patients, family members, re-
searchers, health care professionals and people combining
several roles) and country of residence. Eighty invitations
were sent out by email aiming to get a minimum of fifteen
participants per think tank. Participants’ sampling and invi-
tation were done by the conference organisation commit-
tee. Forty-nine people responded. They were all contacted
by the first author through email to confirm participation
and complete a sociodemographic survey.
Only one adult patient responded to the invitation,
perhaps because most people affected by CDG experi-
ence considerable cognitive and physical impairment,
which limit their ability to engage in speaking-based
activities. To protect the confidentiality of the
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patient’s statements, the categories “patient” and
“family member” were grouped together. Participants
were further divided into “researcher”, “health care
professional” and “multiple roles”. Subsequently, par-
ticipants from each group were randomly assigned to
one of the think tanks to guarantee a similar distribu-
tion per category (see Table 1). One person from the
original sample did not show up and another one was
re-assigned to an ensuing think tank due to a flight
delay.
All think tanks were conducted in English. They lasted
ninety minutes on average and were led by one moder-
ator (CF) together with two observers (PV, JJ) who sum-
marised the main discussion topics at the end of each
think tank. Discussion was elicited based on a brief pres-
entation reporting the findings of a study about CDG
civic mobilisation in Portugal. Transitioning from one
question to the following was done when participants
showed to have nothing else to add. Participants were
offered the opportunity to comment on think tank sum-
maries and to make final observations. The summaries
were also used to assess whether new themes emerged
in subsequent think tanks. After the third think tank, no
original material was added. This determined theoretical
saturation [29], leading to the discontinuation of data
collection.
Participants
Forty-eight participants residing in twenty countries
participated in the think tanks (Table 1). The majority
were female (33/48) and had a post-graduate degree
(26/48). The sample included eighteen patients/family
members, seven researchers, seven health care profes-
sionals and sixteen people combining at least two of
these roles. Most participants had experience with
CDG for less than ten years (34/48) and half were
involved in patient organisations.
Table 1 Participants’ sociodemographic characteristics
Characteristics TOTAL N = 48 Think Tank 1 (n = 16) Think Tank 2 (n = 15) Think Tank 3 (n = 17)
Type of participants
Patient/Family Membera 18 6 5 7
Researcher (clinical or non-clinical) 7 5 1 1
Health Care Professional 7 1 4 2
Multiple Rolesb 16 4 5 7
Country of Residence (continent)c
Europe 31 10 10 11
North America 11 3 3 5
Otherd 6 3 2 1
Gender
Female 33 11 10 12
Male 15 5 5 5
Education
PhD 13 6 4 3
MA/MSc 13 3 2 8
Bachelor/High School 22 7 9 6
Experience CDG (Years)
<5 22 7 6 9
5–9 12 4 4 4
≥ 10 14 5 5 4
Involvement in patient organisation
Yes 24 6 7 11
No 24 10 8 6
aIt includes 1 patient and 17 family members
bIt includes participants with more than one role: family member and non-clinical researcher (n = 1); family member and health care professional (n = 4); clinical
researcher and health care professional (n = 8); family member, clinical researcher and health care professional (n = 3)
cIt includes the following countries: Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Netherlands, Slovak
Republic, Spain, Sweden, Turkey, UK, USA, and United Arab Emirates
dIt includes participants from Asia (n = 2), Australia (n = 2) and South America (n = 2)
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Data analysis
Audio files from the think tanks were transcribed verba-
tim by freelance transcribers and checked for accuracy.
The data were analysed with the assistance of NVivo 11
employing inductive and deductive approaches to inter-
pretational analysis. Open, axial and selective coding,
and the constant-comparison method [29] facilitated the
emergence of inductive categories and core themes.
First, the data were broken down into tentative categor-
ies (open coding), which were subsequently put together
into themes by identifying the connections between
them (axial coding). Data from each think tank were
then examined to select core themes (selective coding)
and iteratively compared with data from other think
tanks (constant comparison). This led to the identifica-
tion of two core themes: participants’ needs (including
“information needs”, “health care needs”, “psychosocial
needs” and “representation needs”); and, strategies pro-
posed to address them (including “strategies developed
by patient and advocacy groups”, “strategies to deal with
health and social care needs” and “online strategies to
disseminate information and bolster research”). During
selective coding, inductive themes were loaded with the-
oretical sensitivity in consultation with the existing lit-
erature [29], i.e. theoretical codes [30] were developed
by “infusing” empirical themes with theory. Themes
linked to patients’ needs emerged close to the formula-
tions used in the literature requesting no adaptations.
Themes associated with “strategies to address chal-
lenges” were deductively reformulated as “social innova-
tions” given their resemblance with the concept [24, 25].
Strategies used to guarantee the rigour and quality of
research included triangulation of data sources, which
were collected in three different moments in time from
people with various origins, roles and stakes in the field
of CDG, and analyst triangulation, with CF leading the
analysis and SS collaborating in the development of the
coding framework and in the phase of selective coding.
Quotes from the think tanks are presented using aggre-
gate attributes in the case of patients and family mem-
bers to protect the confidentiality of all participants’
statements.
Results
The unmet needs experienced by participants and the
social innovations proposed to overcome them are illus-
trated by direct quotes drawn from the think tanks pre-
sented in the text and supplemented by Table 2 and
Table 3, respectively.
Needs confronting people affected by CDG
Participants stated that the complexity of and limited
knowledge about CDG impose several challenges on
people affected by the illness, including insufficient
access to information, quality health care and psycho-
social support, and limited representation of CDG pa-
tients and caregivers in research and civic mobilisation.
Information needs
Accessing reliable information is a key concern for many
CDG families. According to professionals, lack of access
to physicians who are knowledgeable about CDG limits
families’ ability to obtain accurate information (1.1a).
Difficulties in acquiring information, particularly about
experimental treatments (1.2a), cause considerable doubt
and anxiety to parents:
“But how do we get hold of the right physicians? How
do we get the right information?” (Patient/Family Mem-
ber 8).
Some participants overcome informational needs by
resorting to social media platforms created by CDG fam-
ilies internationally. However, extending information to
all members of the CDG community can be complicated
by language barriers (1.3a) and the perils of relying on
unverified information, particularly where it concerns
the unknown effects of experimental treatments:
“When patients start exchanging information (…) [experi-
mental] treatments come to play. There’s a lack of robust
information about their effects and it can even become
dangerous, either medically or financially.” (Professional 3).
Health care needs
Unmet needs for health care are associated with the rar-
ity of CDG and the complexity of its clinical presenta-
tion. They are especially evident with respect to
diagnosis. In the countries and regions where genetic
testing is unavailable (2.1a), CDG has extremely low
prevalence rates. This suggests that CDG may be
under-diagnosed globally. Several participants also
stated that they received misdiagnoses or diagnoses
with long delays. Failure to obtain a correct diagnosis
within a reasonable time frame can have a significant
negative impact on patients’ physical and psycho-
logical outcomes.
“It took us 13 years before we got the diagnosis and
they [daughters] were both diagnosed 2 years ago. How
we got the diagnosis finally was actually a result of co-
operation between patient organizations.” (Patient/Family
Member 9).
“She [daughter] was considered probably to just have a
cerebella problem. She was actually tested twice (…) and
the results came back negative. So, it wasn’t until she
was 14, and she actually had quite a deterioration, that
she was tested again.” (Multiple Roles 3).
Many health care professionals lack knowledge about
the existence of CDG (2.2a–b), which often leads to
delays in referrals for adequate genetic testing and to
under-diagnosing:
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“For a lot of physicians, CDG seems to be quite low on
the testing. One, because they don’t know about it. And
two, they think: ‘well, maybe it’s not worth it to test be-
cause there’s no known treatment’.” (Multiple Roles 16).
Specialist physicians also express difficulties keeping
up with the complexities of the disease. CDG is a multi-
system condition that affects many bodily functions and
has a variable clinical presentation. This challenges the
development of a unified standard approach to deal with
the variety of symptoms that may arise during a patient’s
life course (2.3a). These difficulties are further intensified
by the: existence of ultra-rare CDG types on which there
is limited clinical knowledge; unavailability of genetic
and clinical expertise in some countries and regions, and
restrictive cross-border testing regulations (2.1a); and,
resistance by some professionals to contact other med-
ical experts (2.5a).
Research on CDG has not been a priority funding area
for the pharmaceutical industry. This limits the amount
of investigation done on CDG, as well as clinical trials,
which undermines treatment discovery (2.4a). Inability
to rely on a treatment increases families’ dependence on
health care provision, rendering experiences with
inappropriate care delivery especially worrisome and
exasperating:
“We were discharged by the neurologist (…). And I’m
like: ‘What? My kid has a condition and one of the main
symptoms is a neurological problem and you’re dischar-
ging me? (…).’ The lack of knowledge (…) can be threat-
ening.” (Patient/Family Member 13).
“We wanted to know [our son’s diagnosis] because we
had another son who passed away at 2 months old with-
out known causes. (…) Not getting the information at the
right time is very frustrating because (…) within a couple
of years one can be dead. (…) From our first experience,
Table 2 Unmet health and informational needs identified in
think tank discussions – supplementary quotes
1 Information unmet needs
1.1 Limited clinical information
[1.1a]: Multiple Roles 1: “They [parents] don’t know where to get
the information and, being so rare, a lot of very good clinicians
don’t have that information.”
1.2 Limited information about experimental treatments
[1.2a] Patient/Family Member 5: “There’s a lot of information in the
Internet about CDG but we cannot say whether it’s right or wrong.
We already talked about Mannose [experimental treatment]. One
says that’s the trick and others say: ‘Oh no, that’s not working’.”
1.3 Language barriers
[1.3a] Patient/Family Member 16: “All the info we got about CDG,
we found on our own. (…) We found a Facebook CDG community
group where we got answers. (…) We would like to disseminate this
information for our Czech families. But (…) we don’t have so much
time and energy, and we need to translate everything to Czech.”
2 Health care unmet needs
2.1 Problems with diagnosis
[2.1a] Professional 7: “In South America, at least in Chile, (…) if I’m
suspecting a patient to have a CDG, I’m not able to request the
testing and this is a big issue. I know that the testing is available in
Argentina and Brazil, but we’re struggling to send the biological
samples across the border (…) because we have more rules for
biological samples.”
2.2 Professionals’ limited awareness of CDG
[2.2a] Patient/Family Member 1: “When I have to go to the
emergency of a local hospital, they don’t know anything about
CDG. (…) And when I got too many side effects, they just said:
‘Everything can be due CDG’. (…) So how can you create more
awareness among doctors?”
[2.2b] Multiple roles 9: “I feel that in our country [Italy] knowledge
about CDG is now rather consolidated among paediatricians and
metabolic doctors but it is not a sufficiently known among
physicians that have adult patients in their care and also not, for
example, among neurologists.”
2.3 Complexities of CDG
[2.3a] Multiple Roles 8: “One difficulty for the professionals is that
CDG is a rapid and ever-growing group of disorders. So, even for
professionals who are really interested in CDG, it’s a real task to be
on top of the new diseases. (…) We are all limited for the time and
efforts that we can put into the subject. We need to develop infor
mation packages that we can resort to.”
2.4 Inexistence of treatment
[2.4a] Multiple roles 1: “Researchers are not as interested [in rare
diseases] because it’s hard to bring money in and pharmaceutic
companies are not interested because it’s a very small market.”
2.5 Unsatisfying care delivery
[2.5a] Multiple Roles 10: “We have been in three different cities in
the United States taking our daughter for care and one challenge
that we definitely encounter is that not all doctors want to reach
out to someone who may be a medical expert in a rare disease.”
3 Psychosocial needs
3.1 Distress upon diagnosis
[3.1a] Patient/Family Member 14: “We felt really alone [after
receiving the diagnosis], because we could not understand what
CDG was, what had happened: ‘And now? We go home with our
child and what? What future will he have?”
Table 2 Unmet health and informational needs identified in
think tank discussions – supplementary quotes (Continued)
3.2 Diminished quality of life
[3.2a] Patient/Family Member 18: “In the UK we’re really lucky
because my son has been given disability living allowance and also
[my husband was given] a carer’s allowance. So as long as he
[husband] looks after him for over 40 h a week, he gets paid a
certain amount of money by the government and also he is
allowed to work to up to 16 h a week.”
[3.2b] Multiple Roles 11: “There are lot of things [welfare benefits]
that are really excellent in Germany. I believe in Sweden it should
be as well, even better probably. (…) That might be a good
argument to tell the insurance companies: ‘They have more
resources so why can’t you give us that?”
4 Representation needs
[4a] Professional 7: “People in Latin America don’t have the culture of
associating (…). Also, their model of clinical relationship is a little
different from the European or North American. My patients, I always
ask if they want to contact other families and usually they don’t want
to.”
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unfortunately, we became a little bit less trusting of any
doctor.” (Patient/Family Member 3).
Difficulties in obtaining care adequate to their needs
causes concern and frustration to families. Such adversi-
ties led some participants to reduce their trust on health
care professionals, while others reported going to great
lengths to overcome local limitations in expertise by
mobilising transnational health care resources:
“Unfortunately, the country we live in and the country
we are from have very limited knowledge and very lim-
ited professionals, so we have to do everything on our
own. (…) We reached out to Professor Jaak Jaeken
[Belgium], to Doctor Patterson [United States]. We had
to go to a lab to draw blood, arrange with FedEx and get
a doctor’s signature to be able to ship it abroad.” (Pa-
tient/Family Member 2).
Psychosocial needs
Obtaining a CDG diagnosis was highly distressful for
many families given the uncertainty about the child’s
prognosis and the family’s future (3.1a). Having a child
with CDG often means that one parent has to quit her/
his professional career to become a full-time caregiver.
“I take care of my daughter and they [doctors, teachers]
just don't understand (…) that they're clocking in at
8A.M. and they're off at 5P.M. and we are working 24h
shifts at home. We don't get breaks at weekends. We work
7 days a week.” (Multiple roles 10).
Taking a leave from work or quitting altogether im-
pacts families’ incomes on different degrees depending
on specific national regulations and existing social sup-
ports for long-term medical disability (3.2a–b). More-
over, it impacts families’ quality of life, which can be
substantially reduced when emotional, social and finan-
cial support are insufficient or lacking:
“No one can understand what it means for one of the
parents to stop his professional life. And apart from that,
what is your life? Because our children don’t spend only
hours at the hospital, but also with therapies. (…) It’s im-
portant for us parents to make society understand that
it’s (…) about the quality of life of our family.” (Patient/
Family Member 14).
Representation needs
Some participants expressed concern that only a limited
number of patients and families are actively involved in
advocacy activities:
“I think we have a misrepresentation here [world con-
ference] of parents of CDG patients. (…) It’s great to have
all these family members here that are getting involved
and participating and sharing information, but that’s a
minority.” (Professional 3).
Patient and public involvement is limited by cultural,
financial and geographical barriers (4a) that diminish
Table 3 Social innovations identified in think tank discussions –
supplementary quotes
1 Civil society innovations
1.1 Providing information and support to families
[1.1a] Multiple Roles 6: “My doctors didn’t know what was going
on and I reached out to one of the families in New Zealand. She
[mother] told me she could take our data to her hospital and show
it to her physician, and they took my daughter into account (…)
and we just immediately got feedback. (…) So getting those
resources out to parents would be very helpful.”
1.2 Advocating for social and financial support
[1.2a] Patient/Family Member 13: “We’re in such small numbers in
each country. I was wondering: ‘Would it make sense to create
some sort of CDG Europe?’ (…) Then maybe it would be easier to
approach insurance companies. And it actually would be easier to
access funding (…)”.
1.3 Promoting research
[1.3b] Multiple Roles 16: “It is [important] for physicians across the
globe to begin to really collaborate and learn from each other in a
very different way that we’ve traditionally done. (…) So I think
that’s something else parents and family organizations can push
towards. (…) We want lots of places (…) all around the world
talking to each other, so that we’re sharing the new things that are
getting learned in a faster, easier way.”
2 Care-related innovations
2.1 Increasing professionals’ awareness
[2.1a] Multiple Roles 14: “If physicians are going to take their board
examinations, they will learn about certain diseases, and people
learn quickly if they know that they’re likely to be asked about
CDG. (…) But another thing (…) is to give conference talks, to
publish articles about it.”
2.2 Improving care approaches
[2.2a] Professional 3: “I think you have to identify a few important
problems that are common within the group of CDG patients and
then try to find information that is already there, just a
retrospective analysis. And then, maybe try to put forward a few
strategies and test them in the population so you can make
progress in this disease group.”
[2.2b] Multiple Roles 8: “The next thing that should happen is that
we exchange what we think about it with doctors in other
countries who have treated patients with the same problem. (…)
And (…) we can identify what has been done and what was the
outcome. This will enable us to get better treatment strategies.”
2.3 Families’ involvement in treatment
[2.3a] Patient/Family Member 18: “Sometimes we [parents] just
have to think: ´I’m going do it and get over the embarrassment.
(…) If I don’t understand, I’m going to keep repeating my question
until I get an answer.”
3 Digital innovations
3.1 Developing a CDG expertise online platform
[3.1a] Patient/Family Member 11: “Structured online platforms are
really the way ahead. Controlled information could be
disseminated, questions could be asked but, yes, it does need to
be an international platform.”
[3.1b] Multiple Roles 8: “It’s important that we have different
country representatives because resources and health structures are
very different in different countries.”
[3.1c] Professional 3: “The information exchanged in a platform like
that has to be controlled medically (…) it can’t just be an open
platform of communication where information is exchanged. That
can sometimes be even dangerous to patients.”
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people’s ability and willingness to engage in peer sup-
port, research (e.g. setting priorities) and advocacy –
something that participants found was imperative to
change:
“We need to get better resources and better means of
getting families that are sitting on the countryside,
somewhere in the UK, with very limited financial support
to have a voice in the CDG community as well.” (Mul-
tiple Roles 8).
Social innovations to overcome the unmet needs of
people affected by CDG
Participants suggested several innovative strategies to
address the needs expressed by the CDG community.
Some are concerned with initiatives emerging from and
seeking to overcome the needs of patients and families
(“civil society innovations”). Others are more directly re-
lated to dealing with challenges at the health and social
care level (“care-related innovations”). And yet, others
entail the use of digital technologies to address the com-
munity’s multi-level needs (“digital innovations”) [24].
Civil society innovations
Participants’ proposals for civil society innovations aim
to mitigate the negative effects of unmet needs for infor-
mation, psychosocial support and representation. Face-
to-face and online peer support were considered the
most effective ways to assist families in obtaining the in-
formation and psychosocial support needed (1.1a).
Overcoming representation needs meant reaching out
to and involving a more heterogeneous group of fam-
ilies in, and within, different countries. Mobilising
CDG families to take part in advocacy groups can
help increase their lobbying power with the govern-
ment and care sponsors (1.2a):
“I think you have strength in numbers and it might be
useful even to think of whether you call it Global CDG.
(…) I think when you have a group like that you could
also advocate with your government representatives and
that’s a very powerful voice.” (Multiple roles 14).
Engaging in advocacy can also help families connect
with physicians and clinical researchers, and increase
their information about and participation in inter-
national studies (1.3b) concerned with advancing re-
search on CDG.
“From a doctor’s perspective, (…) if you have one pa-
tient, it’s difficult to allocate a lot of interest, time and
motivation. (…) So, from a patient’s perspective, you have
to identify these people who have more than one patient
and then you have to make sure that other patients know
as well that they’re interested, motivated, knowledgeable.”
(Professional 3).
Care-related innovations
Adapting health care provision to the needs of patients
and families requires social innovations centred around
three goals: increasing professionals’ awareness of CDG,
improving care for CDG, and involving patients and
families in treatment decision-making. The first can be
achieved by including CDG in medical board examina-
tions, disseminating information about CDG through
public talks and publications (2.1a), and adding CDG to
diagnostic checklists:
“We should get it [CDG] on a checklist and if they see
a child with, for example, an unexplained developmental
delay, then they send with all the analyses being
requested also a request for a CDG analysis.” (Multiple
roles 11).
Developing quality care approaches to CDG requires
identifying successful care practices, testing them among
specific CDG groups, discussing the results with col-
leagues internationally and disseminating selected best
practices (2.2a–b).
Finally, to enable patients and families to get involved
in treatment, it is necessary to empower parents to clar-
ify doubts (2.3a), and provide them with intelligible in-
formation and the opportunity to make decisions:
“I think that parents also need to educate the
physicians. In the hospital where I’m working, I’m also
continuously fighting against my colleagues for not
explaining things to parents. (…) But I think it’s really
important for all parents here to say: ‘OK, I don’t
understand. Please explain it to me again, again and
again’.” (Multiple roles 12).
Digital innovations
Participants stated the need to create an online platform
with “state-of-the-art” knowledge on CDG, and to make
that expertise accessible to patients, families, health care
professionals and researchers worldwide (3.1a) in order
to mitigate the negative effects of information scarcity
and bolster research. They also considered the possibility
of transforming it into a global patient registry enabling
the collection of patients’ clinical and biological data:
“It would be a great idea to create a website where
everybody, internationally, could enter their information
and you can have questionnaires and a patient registry.”
(Multiple roles 11).
To maximise the online CDG platform’s effectiveness
and reach, it should have an international scope, secure
funding, employ staff and be multilingual:
“Those kinds of (online) platforms, when you don’t have
the financial means and time to maintain them, they are
hard to keep. If you could do that, in an international
setting, that would be better because then you can tackle
the language problem.” (Researcher 2).
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Participants also emphasised the importance of
engaging stakeholders from different countries (3.1b),
and expressed concern regarding the need to control the
quality of data (3.1c) and to guarantee its security by
safeguarding families’ data ownership:
“If you can get government support and if industry can
be interested, great! (…) I think the important thing is
that you [patients/families] own the data. This is your
data.” (Multiple roles 14).
Discussion
This study set out to assess the needs of people affected
by CDG and to elicit innovative strategies to address
them using a think tank methodology that engaged
stakeholders from twenty countries across the globe.
Our findings revealed four types of unmet needs: infor-
mation, health care, psychosocial and representation
needs. The former three attest to the mismatch between
patients’ multi-level needs and the services available to
them. They also suggest that, albeit laudable, rare dis-
eases policy in European Union Member States [31] and
the United States [32] has so far proved insufficient to
eliminate inequalities in access to quality care among
people affected by CDG. Representation needs evidence
the difficulties involved in engaging vulnerable groups in
participatory initiatives aimed at promoting their rights
and interests [22, 33]. CDG patients and families are
represented by patient organisations in national and
international alliances which have a say in rare diseases
policy and health care governance. However, representa-
tion may be strongly influenced by a few resourceful and
vocal patients and families. The voices of the disengaged
majority are rarely heard.
Limited access to quality care has severe consequences
for CDG patients and families. It undermines their
access to prompt diagnosis, which can cause distress and
lead to deteriorating health. Moreover, it may be con-
tributing to underestimate the incidence of CDG. This
has a negative impact on the amount of resources allo-
cated to professional training, service delivery and re-
search, thus reducing the availability of information,
specialised care, rehabilitation services and treatment.
Although some families are able to seek cross-border
care services, this may result in delays in obtaining ne-
cessary care and cause additional financial strain (e.g. in-
ability to obtain expenses reimbursement) [34]. CDG
families are also confronted with psychosocial burden.
Uncertainty about disease prognosis, lack of effective
treatments, costly therapies and feelings of isolation
take a major toll on families’ quality of life. These
findings are supported by studies focusing on people
affected by other rare diseases, and their caregivers,
who also report unmet needs for information, health
and social care [6–9].
Bridging and filling the equity gap in access to care for
people with rare diseases requires patient-oriented research
that can inform decision-making concerned with care qual-
ity improvement [35]. It also demands involvement of mul-
tiple stakeholders. Sustainable quality improvement entails
a collective effort grounded on networks of people and ac-
tions aimed at making care responsive to patients’ needs
[12]. Our study has made a first attempt at rallying such a
network by bringing together lay and professional experts
from around the world to elicit community-framed innova-
tions to improve the quality of care and life of people af-
fected by CDG.
Participants proposed civil society, care-related and
digital innovations, which include peer-support commu-
nities, web-based information resources and an online
expertise platform. Altogether, these innovations can re-
dress system failures by facilitating access to a “virtual
empowerment toolkit” [6] that can foster knowledge
sharing, improve disease management, increase quality
of life and promote a sense of community that is crucial
for public and patient involvement [10, 36, 37]. Such an
empowering device might also help to promote people-
centred adjustments to health and social care provision
by drawing awareness and providing the impetus neces-
sary to invest on tailor-made professional training, ac-
cessible diagnostic tools, intelligible information, optimal
management of multi-disciplinary care delivery and dia-
logic patient/family-provider relationships [38] enabling
shared treatment decision-making.
The social innovations proposed by participants also
carry the potential to enhance fundamental and transla-
tional research by connecting patients, professionals and
researchers, and enabling the donation of patients’ clin-
ical data and biological material for research. Some of
these innovations are starting to emerge. Rarecommon-
s.org, for example, is an online platform recently created
to collect data and develop research on rare diseases
through the participation of families and physicians.
Digital innovations such as this one can facilitate the co-
production of knowledge and technology with the par-
ticipation of citizens. However, they are not a panacea
and they carry ethical, legal and social implications
(ELSI). Both lay and professional stakeholders need to
be involved in decision-making about ELSI regulation
and management [39–41], particularly in regard to is-
sues related to confidentiality, informed consent, owner-
ship, donation, storage and sharing of biological, clinical
and personal data, and the return of research results to
the public [42]. In the case of CDG and other groups
who have been at the margins of decision-making, this
may require the creation of participatory spaces specific-
ally designed to enable all stakeholders to voice their
concerns, find middle ground and jointly deliberate on
policies, care and research sensitive to their needs,
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values and preferences [43]. In other words, it may
require spaces in which formerly detached groups can
come together to establish bidirectional partnerships
[44] and uncover the elements of expert and patient
knowledge that are key for the co-production of patient-
centred care and research.
Participants in our study stated that broader represen-
tation is critical to achieving equity in care and reducing
potential research biases resulting from skewed popula-
tion samples. As other studies with marginalised groups
suggest, creating supportive participatory environments,
attending to participants’ motivations for involvement,
facilitating access to resources and providing opportun-
ities to effect change are key to enabling inclusive public
and patient involvement [2, 22, 33]. However, in the spe-
cific case of CDG patients, this may not suffice to
achieve broad representation. CDG is an early onset
chronic disease that can cause considerable impairment,
not least to speech. This makes it challenging to involve
large groups of patients using conventional research
methods. More creative methodological designs are
needed to engage CDG patients in decision-making and
research. One option might be the use of creative visual
methods (e.g. photography, video, acting performance)
[45]. Far from being a “magic bullet” [46], these methods
can nonetheless help the CDG community to participate
more fully in knowledge co-production and care quality
improvement.
Strengths and limitations
The use of a think tank methodology is a key strength of
this study. Meeting face-to-face allowed participants to
listen to and reflect about each other’s contributions
enriching the depth of the data collected. Furthermore,
it afforded CDG stakeholders from various backgrounds
and nationalities an unprecedented opportunity to share
their experiences and confront different points of view.
A post-conference satisfaction survey including 33 out
of the 48 think tank participants showed high receptivity
to this initiative, with 80% of participants recommending
a follow-up in the upcoming world conference.
This study also has some limitations. First, it does not
include representatives of disengaged CDG patients and
families. Previous studies have found that people with
low education tend to report fewer unmet care needs
than higher educated people [9]. Most participants in
this study were highly educated, suggesting it may be
providing a comprehensive depiction of the needs expe-
rienced by the CDG community. Nevertheless, to over-
come this limitation and frame a fair set of priorities for
action, it is essential to carry further research engaging
the diversity of patients and families affected by CDG. A
second limitation of the study is associated with think
tanks being conducted in the English language. This
may have favoured native speakers in setting forth their
views even though all participants were able to express
themselves.
Conclusion
This is one of the few studies to engage lay and profes-
sional experts globally to collectively assess the needs of
people affected by CDG and devise social innovations to
address them. The social innovations proposed have eth-
ical, legal and social implications that need to be assessed
and regulated with the involvement of all stakeholders. To
foster the participation of people affected by CDG in the
governance of care and research, it is necessary to create
participatory spaces where they can fully express their
views. That may require the use of innovative strategies
and methods to recruit and involve a diverse section of
the CDG community in decision-making concerned with
the promotion of patient-centred care.
Abbreviations
CDG: Congenital disorders of glycosylation; ELSI: Ethical, legal and social
implications
Acknowledgements
We are grateful to all participants in this study and to Donna Krasnewich
(National Institute of Health, USA) whose expertise greatly improved this
manuscript. We also thank the CDG & Allies – Professionals and Patient
Associations International Network.
Funding
FCT - Foundation for Science and Technology (Portuguese Ministry of
Science, Technology and Higher Education), the Social European Fund and
the POPH Programme supported this study with research grants: SFRH/BPD/
111344/2015 (CF) and IF/01674/2015 (SS).
Availability of data and materials
The datasets generated during the current study are not publicly available to
safeguard participants’ confidentiality but are available from the
corresponding author on reasonable request.
Authors’ contributions
CF, VF and SS designed the study. CF, VF, PV and JJ carried out data
collection. CF and SS performed data analysis and interpretation. CF, VF, SS,
PV, EM and JJ drafted the original manuscript. All authors participated in the
revision of the manuscript and on preparing a response to reviewers. All
authors read and approved the final version of the manuscript and are
accountable for the work presented.
Ethics approval and consent to participate
Ethics approval was obtained following project approval by the Foundation
for Science and Technology (Portuguese Ministry of Science, Technology and
Higher Education). The study followed the Code of Ethics of the International
Sociological Association. All participants provided prior written informed




VF is the founder of the Portuguese Association for Congenital Disorders of
Glycosylation (APCDG-DMR). CF’s travel expenses to conduct the think tanks
were funded by APCDG-DMR.
de Freitas et al. BMC Health Services Research  (2017) 17:682 Page 9 of 11
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
2Institutional address 1: Rua das Taipas 135, 4050-600, Porto, Portugal.
3Centre for Research and Studies in Sociology - University Institute of Lisbon,
Porto, Portugal. 4Institutional address 2: Avenida das Forças Armadas,
1649-026, Lisbon, Portugal. 5Founder of the Portuguese Association for CDG
(APCDG), Porto, Portugal. 6Institutional address: Rua Manuel da Fonseca 46,
2820-389, Almada, Portugal. 7Faculdade de Ciências e Tecnologia,
Universidade Nova de Lisboa, Lisbon, Portugal. 8Institutional address:
Glycoimmunology group Lab 3.19 - Departamento Ciências da Vida (Ed
Departamental), Faculdade de Ciências e Tecnologia, 2829-516 Caparica,
Portugal. 9School of Medicine, Tulane University, New Orleans, USA.
10Institutional address: Hayward Genetics Center SL#31, Tulane University
Medical School, 1430 Tulane Ave, New Orleans, LA 70112, USA.
11Department of Pediatrics, Center for Metabolic Disease, University Hospital
Gasthuisberg, Leuven, Belgium. 12Institutional Address: Herestraat 49, 3000,
Leuven, Belgium.
Received: 17 February 2017 Accepted: 18 September 2017
References
1. Haarsma F, Moser A, Beckers M, van Rijswijk H, Stoffers E, Beurskens A. The
perceived impact of public involvement in palliative care in a provincial
palliative care network in the Netherlands: a qualitative study. Health
Expect. 2015;18:3186–200.
2. Brett J, Staniszewska S, Mockford C, Herron-Marx S, Hughes J, Tysall C, et al.
A systematic review of the impact of patient and public involvement on
service users, researchers and communities. Patient - Patient-centered
Outcomes Res. 2014;7:387–95.
3. Mockford C, Staniszewska S, Griffiths F, Herron-Marx S. The impact of patient
and public involvement on UK NHS health care: a systematic review. Int J
Qual Heal Care. 2012;24:28–38.
4. Staley K. Exploring impact: public involvement in NHS, public health and
social care research. INVOLVE: Eastleigh; 2009.
5. Omeni E, Barnes M, MacDonaldDee, Crawford M, Rose D. Service user
involvement: impact and participation: a survey of service user and staff
perspectives. BMC health Serv. Res. 2014;14:491–504.
6. Dwyer AA, Quinton R, Morin D, Pitteloud N. Identifying the unmet health
needs of patients with congenital hypogonadotropic hypogonadism using
a web-based needs assessment: implications for online interventions and
peer-to-peer support. Orphanet J. Rare Dis. 2014;9:83–94.
7. Khangura SD, Tingley K, Chakraborty P, Coyle D, Kronick JB, Laberge A-M,
et al. Child and family experiences with inborn errors of metabolism: a
qualitative interview study with representatives of patient groups. J Inherit
Metab Dis. 2015;39:139–47.
8. Røthing M, Malterud K, Frich JC. Balancing needs as a family caregiver in
Huntington’s disease: a qualitative interview study. Health Soc Care
Community. 2015;23:569–76.
9. van Walsem MR, Howe EI, Iversen K, Frich JC, Andelic N. Unmet needs for
healthcare and social support services in patients with Huntington’s disease:
a cross-sectional population-based study. Orphanet J. Rare Dis.
2015;10:124–34.
10. Oliveira P, Zejnilovic L, Canhão H, von Hippel E. Innovation by patients with
rare diseases and chronic needs. Orphanet J. Rare Dis. 2015;10:41–9.
11. Owen R, Macnaghten P, Stilgoe J. Responsible research and innovation:
from science in society to science for society, with society. Sci Public Policy.
2012;39:751–60.
12. Renedo A, Marston C. Developing patient-centred care: an ethnographic
study of patient perceptions and influence on quality improvement. BMC
Health Serv Res. 2015;15:122–33.
13. Jaeken J, Hennet T, Matthijs G, Freeze HH. CDG nomenclature: time for a
change! Biochim Biophys Acta. 1792;2009:825–6.
14. Scott K, Gadomski T, Kozicz T, Morava E. Congenital disorders of glycosylation:
new defects and still counting. J Inherit Metab Dis. 2014;37:609–17.
15. Thiel C, Körner C. Therapies and therapeutic approaches in congenital
disorders of glycosylation. Glycoconj J. 2013;30:77–84.
16. Jaeken J. Congenital disorders of glycosylation. Ann N Y Acad Sci. 2010;
1214:190–8.
17. Sparks SE, Krasnewich DM. Congenital disorders of N-linked glycosylation
pathway overview. In: Pagon RA, editor. Gene Rev. Seattle: University of
Washington; 2014.
18. De Lonlay P, Seta N, Barrot S, Chabrol B, Drouin V, Gabriel BM, et al. A broad
spectrum of clinical presentations in congenital disorders of glycosylation I:
a series of 26 cases. J Med Genet. 2001;38:14–9.
19. Jaeken J, Mattijs G. Congenital disorders of glycosylation. Annu Rev
Genomics Hum Genet. 2001;2:129–51.
20. Goreta SS, Dabelic S, Dumic J. Insights into complexity of congenital
disorders of glycosylation. Biochem Medica. 2012;22:156–70.
21. Theodore M, Morava E. Congenital disorders of glycosylation: sweet news.
Curr Opin Pediatr. 2011;23:581–7.
22. De Freitas C, Martin G. Inclusive public participation in health: policy,
practice and theoretical contributions to promote the involvement of
marginalised groups in healthcare. Soc Sci Med. 2015;135:31–9.
23. Phills JA, Deiglmeier K, Miller DT. Rediscovering social innovation. Stanford
Soc Innov Rev. 2008;6:34–43.
24. Mason C, Barraket J, Friel S, O’Rourke K, Stenta C-P. Social innovation for the
promotion of health equity. Health Promot. Int. 2015;30:ii116–25.
25. Mulgan G, Tucker S, Ali R. Sanders B. What it is, why it matters and how it
can be accelerated. Oxford: Social Innovation; 2007.
26. Katerndahl D, Crabtree B. Creating innovative research designs: the 10-year
methodological think tank case study. Ann Fam Med. 2006;4:443–9.
27. Brown RT, Wiener L, Kupst MJ, Brennan T, Behrman R, Compas BE, et al.
Single parents of children with chronic illness: an understudied
phenomenon. J Pediatr Psychol. 2008;33:408–21.
28. Patton MQ. Qualitative research and evaluation methods. Los Angeles: Sage
Publications; 2015.
29. Strauss AL, Corbin JM. Basics of qualitative research. Thousand Oaks: Sage;
1998.
30. Charmaz K. Constructing grounded theory: a practical guide through
qualitative analysis. London: Sage Publications; 2006.
31. Rodwell C, Aymé S. Rare diseases policies to improve care for patients in
Europe. Biochim Biophys Acta. 1852;2015:2329–35.
32. Williams P. Policy framework for rare disease health disparities. Policy, Polit.
Nurs. Pract. 2011;12:114–8.
33. Montesanti SR, Abelson J, Lavis JN, Dunn JR. Enabling the participation of
marginalized populations: case studies from a health service organization in
Ontario. Canada Health Promot Int. 2016:1–14.
34. Freitas C de, Mendes Á. A resiliência da saúde migrante: itinerários
terapêuticos plurais e transnacionais. REMHU Rev Interdiscip da Mobilidade
Humana. 2013;21:69–92.
35. Facey K, Hansen HP. The imperative for patient-Centred research to develop
better quality Services in Rare Diseases. Patient - Patient-Centered
Outcomes Res. 2015;8:1–3.
36. De Freitas C. Aiming for inclusion: a case study of motivations for
involvement in mental health-care governance by ethnic minority users.
Health Expect. 2015;18:1093–104.
37. Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare
diseases community. Lancet. 2008;371:2048–51.
38. Miller D, Steele Gray C, Kuluski K, Cott C. Patient-centered care and patient-
reported measures: Let’s look before we leap. Patient - patient-centered
outcomes res. New Zealand. 2015;8:293–9.
39. Lemke AA, Halverson C, Ross LF. Biobank participation and returning
research results: perspectives from a deliberative engagement in south side
Chicago. Am J Med Genet. 2012;158A:1029–37.
40. Moodley K, Sibanda N, February K, Rossouw T. “It’s my blood”: ethical
complexities in the use, storage and export of biological samples:
perspectives from south African research participants. BMC Med Ethics.
2014;15:4.
41. Samorinha C, Severo M, Machado H, Figueiredo B, de Freitas C, Silva S.
Couple’s willingness to donate embryos for research: a longitudinal study.
Acta Obstet Gynecol Scand. 2016;95:912–21.
42. McCormack P, Kole A, Gainotti S, Mascalzoni D, Molster C, Lochmüller H,
et al. “You should at least ask”. The expectations, hopes and fears of rare
disease patients on large-scale data and biomaterial sharing for genomics
research. Eur. J Hum Genet. 2016;24:1403–8.
43. De Freitas C. Public and patient participation in health policy, care and
research. Porto Biomed J. 2017;2:31–2.
de Freitas et al. BMC Health Services Research  (2017) 17:682 Page 10 of 11
44. Badiu C, Bonomi M, Borshchevsky I, Cools M. Developing and evaluating
rare disease educational materials co-created by expert clinicians and
patients: the paradigm of congenital hypogonadotropic hypogonadism.
Orphanet J Rare Dis. 2017;12:57.
45. Gauntlett D. Creative explorations: new approaches to identities and
audiences. New York: Routledge; 2007.
46. Lomax H. Contested voices? Methodological tensions in creative visual
research with children. Int J Soc Res Methodol. 2012;15:105–17.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
de Freitas et al. BMC Health Services Research  (2017) 17:682 Page 11 of 11
